Predict your next investment

ENERGY & UTILITIES | Renewables / Bio-energy
ls9.com

See what CB Insights has to offer

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$76M

Valuation

$0000 

About LS9

LS9, the Renewable Petroleum Company, is a privately-held industrial biotechnology company pursuing the commercial development of renewable fuels and chemicals. LS9 is applying synthetic biology to produce proprietary biofuels that are compatible with existing fuel distribution and consumer infrastructure, as well as high-value industrial chemicals. LS9 is the pioneer in the commercial development of fermentation derived hydrocarbon biofuels and its patent-pending Renewable Petroleum products are custom engineered in the lab to address immediate market needs for clean energy alternatives to petroleum.

LS9 Headquarter Location

600 Gateway Boulevard

South San Francisco, California, 94080,

United States

650-243-5400

Latest LS9 News

Biomaterials Company MycoWorks Appoints Board Director Tjerk De Ruiter

May 12, 2021

Biomaterials Company MycoWorks Appoints Board Director Tjerk De Ruiter Executive leader brings industrial biotech expertise from Corbion, LS9 and Genencor to scale the Fine Mycelium™ technology platform. Author: May 12, 2021 12:18 PM EDT SAN FRANCISCO, May 12, 2021 /PRNewswire/ -- Biomaterials company MycoWorks today announced the appointment of independent Board Director Tjerk de Ruiter, who joins MycoWorks Board Directors Anders Spohr (Novo Holdings), Kiersten Stead (DCVC Bio), and MycoWorks CEO Matt Scullin. De Ruiter brings over 35 years' experience in the governance and scaling of innovative, private and public biotechnology businesses with a focus on enzyme and fermentation technologies, specialty chemicals and synthetic biology. This leadership appointment constitutes part of MycoWorks' strategic expansion following a $45M Series B financing round to accelerate the scale-up of the company's proprietary Fine Mycelium biomaterials platform and the opening of a new plant, which enables ten times previous production capacity. De Ruiter will focus on resourcing MycoWorks with commercial-scale fermentation, enzyme and chemistry solutions towards the product and manufacturing innovations that will bring Fine Mycelium to commercial volumes. De Ruiter also serves as advisor to Novo Holdings and is a board member at NuTek Food Science, with prior positions as Chairman of EuropaBio and the BIO I&E Section Governing Board. "The advanced work that the MycoWorks team is leading through the combination of biotechnology, materials and applied science, and craftsmanship has created a unique opportunity for the company to provide new material solutions that brands and consumers are demanding. I am eager to collaborate with the team as we continue to scale the business and focus our growth of the Fine Mycelium technology," said de Ruiter. MycoWorks is recognized globally for its creation of Fine Mycelium™, a breakthrough in materials science and biotechnology that refers both to the company's proprietary process and the class of materials exclusive to MycoWorks. Materials are grown to brand partners' specifications for performance, aesthetic features and more, unlocking new design possibilities for the fashion and footwear industries. For more information, please visit MycoWorks.com or contact: BPCM Leah Lefco MycoWorks@bpcm.com About MycoWorksIn 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco based biomaterials company dedicated to bringing new mycelium materials to the world. MycoWorks' patented Fine Mycelium technology is an advanced manufacturing platform and breakthrough in materials science, which engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled strength and durability. View original content: http://www.prnewswire.com/news-releases/biomaterials-company-mycoworks-appoints-board-director-tjerk-de-ruiter-301290035.html

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing LS9

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LS9 is included in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

302 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

LS9 Patents

LS9 has filed 17 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/15/2013

1/30/2018

Food additives, Biofuels, Fatty acid esters, Methyl esters, Alkene derivatives

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/15/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/30/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Food additives, Biofuels, Fatty acid esters, Methyl esters, Alkene derivatives

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.